Clinical Trial Update: A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS [Phase 3]

View source ↗

Summary

A Phase IIIb multicenter international trial evaluating EK-12 for Relapsing-Remitting Multiple Sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• EK-12

Snippet

Sponsor: Bosnalijek D.D | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: TERMINATED